News from nkt therapeutics A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 08, 2014, 08:05 ET
NKT Therapeutics logo

NKT Therapeutics Presents Data on its Therapeutic Program Targeting Sickle Cell Disease at the American Society of Hematology

NKT Therapeutics (NKTT), a clinical stage biotechnology company, presented this week positive Phase 1 clinical data for its lead compound NKTT120...

Nov 06, 2014, 09:05 ET
NKT Therapeutics logo

NKT Therapeutics to Present Data on its Therapeutic Program Targeting Sickle Cell Disease at the American Society of Hematology

 NKT Therapeutics, a clinical stage biotechnology company, today announced that its scientists and collaborators will present preclinical and...

Oct 02, 2014, 08:30 ET
NKT Therapeutics logo.  (PRNewsFoto/NKT Therapeutics)

FDA Grants Fast Track Designation to NKT Therapeutics' NKTT120 for the Treatment of Sickle Cell Disease

 NKT Therapeutics today announced that the U.S. Food and Drug Administration has granted Fast Track designation to NKTT120, the company's lead...

Dec 09, 2013, 10:10 ET

NKT Therapeutics' Identifies Novel anti-iNKT Antibodies for Depleting or Activating iNKT Cells

 NKT Therapeutics (NKTT) today presented research results with NKT14 and NKT14m, monoclonal antibodies designed to deplete (NKT14) or activate...

Dec 07, 2013, 10:00 ET
NKT Therapeutics logo.  (PRNewsFoto/NKT Therapeutics)

NKT Therapeutics Reports First Clinical Results with anti-iNKT Antibody in Patients with Sickle Cell Disease

NKT Therapeutics today announced the presentation of initial clinical results with NKTT120, a monoclonal antibody designed to suppress the chronic...

Dec 08, 2012, 09:00 ET
NKT Therapeutics logo.  (PRNewsFoto/NKT Therapeutics)

NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease

NKT Therapeutics, Inc., a privately held biotechnology company, announced preclinical study results supporting the potential of its lead...